Leveraging Nanodrug Delivery System for Simultaneously Targeting Tumor Cells and M2 Tumor-Associated Macrophages for Efficient Colon Cancer Therapy
Tumor-associated macrophages (TAMs) widely exist in the solid tumors, which participate in the entire course of tumor development and execute momentous impacts. Therefore, manipulating TAMs has been identified as an expecting strategy with immense potential for cancer therapy. Herein, a nanodrug delivery system was leveraged for simultaneously targeting tumor cells and M2-type TAMs for efficient colon cancer therapy. The broad-spectrum anticancer chemotherapeutic drug doxorubicin (DOX) was hitchhiked in a mannose-modified bovine serum albumin (MAN-BSA) carrier. The DOXMAN-BSA nanodrug delivery system was verified to possess feasible physical performances for unhindered systemic circulation and active targeting on colon tumors. DOX@MAN-BSA nanoparticles could be preferentially swallowed by colon tumor cells and M2 TAMs through mannose receptor-mediated endocytosis. Further in vivo antitumor therapy in CT26 colon tumor-bearing mice has achieved remarkable suppression efficacy with satisfactory biosafety. Leveraging the nanodrug delivery system for simultaneously targeting tumor cells and M2 TAMs has contributed a feasible strategy to collaboratively repress the malignant tumor cells and the collusive M2 TAMs for efficient cancer therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
ACS applied materials & interfaces - 14(2022), 45 vom: 16. Nov., Seite 50475-50484 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zeng, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
27432CM55Q |
|---|
| Anmerkungen: |
Date Completed 21.11.2022 Date Revised 21.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsami.2c11534 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348410883 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348410883 | ||
| 003 | DE-627 | ||
| 005 | 20231226040127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsami.2c11534 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348410883 | ||
| 035 | |a (NLM)36327132 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zeng, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Leveraging Nanodrug Delivery System for Simultaneously Targeting Tumor Cells and M2 Tumor-Associated Macrophages for Efficient Colon Cancer Therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2022 | ||
| 500 | |a Date Revised 21.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tumor-associated macrophages (TAMs) widely exist in the solid tumors, which participate in the entire course of tumor development and execute momentous impacts. Therefore, manipulating TAMs has been identified as an expecting strategy with immense potential for cancer therapy. Herein, a nanodrug delivery system was leveraged for simultaneously targeting tumor cells and M2-type TAMs for efficient colon cancer therapy. The broad-spectrum anticancer chemotherapeutic drug doxorubicin (DOX) was hitchhiked in a mannose-modified bovine serum albumin (MAN-BSA) carrier. The DOXMAN-BSA nanodrug delivery system was verified to possess feasible physical performances for unhindered systemic circulation and active targeting on colon tumors. DOX@MAN-BSA nanoparticles could be preferentially swallowed by colon tumor cells and M2 TAMs through mannose receptor-mediated endocytosis. Further in vivo antitumor therapy in CT26 colon tumor-bearing mice has achieved remarkable suppression efficacy with satisfactory biosafety. Leveraging the nanodrug delivery system for simultaneously targeting tumor cells and M2 TAMs has contributed a feasible strategy to collaboratively repress the malignant tumor cells and the collusive M2 TAMs for efficient cancer therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a M2 TAMs | |
| 650 | 4 | |a active targeting | |
| 650 | 4 | |a colon cancer | |
| 650 | 4 | |a nanodrug delivery system | |
| 650 | 4 | |a tumor-associated macrophage | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Mannose |2 NLM | |
| 650 | 7 | |a PHA4727WTP |2 NLM | |
| 650 | 7 | |a Serum Albumin, Bovine |2 NLM | |
| 650 | 7 | |a 27432CM55Q |2 NLM | |
| 700 | 1 | |a Sun, Yanju |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Shuo |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Mingxia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Daijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wentong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhijun |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Hongcai |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Xiuwen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Weifen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS applied materials & interfaces |d 2009 |g 14(2022), 45 vom: 16. Nov., Seite 50475-50484 |w (DE-627)NLM194100049 |x 1944-8252 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:45 |g day:16 |g month:11 |g pages:50475-50484 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsami.2c11534 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 45 |b 16 |c 11 |h 50475-50484 | ||